Walleye Capital’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-28,900
Closed -$341K 4926
2025
Q3
$341K Buy
28,900
+19,600
+211% +$183K ﹤0.01% 2911
2025
Q2
$60.4K Buy
9,300
+2,600
+39% +$17.1K ﹤0.01% 3974
2025
Q1
$39.2K Buy
+6,700
New +$48K ﹤0.01% 3907
2024
Q4
Sell
-5,200
Closed -$29.6K 5276
2024
Q3
$29.6K Buy
5,200
+2,400
+86% +$16.7K ﹤0.01% 4744
2024
Q2
$20.2K Buy
+2,800
New +$24.5K ﹤0.01% 5111

Other funds holding DFTX

Walleye Capital's DFTX Position: Q1 2026 in Review

Walleye Capital opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 35,485 shares worth $671K. The stake represents ﹤0.01% of the portfolio and ranks #2426 among its holdings. This is a return to the name: Walleye Capital previously reported a position in DFTX as recently as Q3 2025.

Walleye Capital first reported a position in DFTX in Q2 2024 and has held it in 3 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Walleye Capital held 35,485 shares of Definium Therapeutics worth $671K as of Q1 2026.
  • Definium Therapeutics was a new Walleye Capital position in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2426 holding.
  • Walleye Capital first reported a position in Definium Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.